奥洛珠单抗联合甲氨蝶呤治疗106周的安全性与疗效
基于三项随机临床试验及其开放标签扩展研究汇总数据,2304例活动性类风湿关节炎患者接受奥洛珠单抗联合甲氨蝶呤治疗。106周内不良事件发生率未见增加,疗效维持稳定。
要点
- 每2周与每4周给药组严重不良事件发生率分别为9.57和9.13每100患者年。
- 106周治疗期间未观察到任何不良事件发生率增加。
- 开放标签扩展期间临床应答率保持稳定,疗效维持至第106周。
核心结论
- 奥洛珠单抗联合甲氨蝶呤的长期安全性和耐受性保持稳定,疗效维持至第106周,支持其作为活动性类风湿关节炎患者的治疗选择。
研究设计与样本
- 汇总三项3期核心随机临床试验及其开放标签扩展研究的数据进行累积分析,共2304例患者接受奥洛珠单抗联合甲氨蝶呤治疗,给药方案为每2周一次或每4周一次。
主要发现
- 每100患者年事件率在奥洛珠单抗每2周组与每4周组分别为:严重不良事件9.57和9.13,严重感染2.95和2.34,胃肠道穿孔0.09和0.05,主要不良心血管事件0.58和0.83,恶性肿瘤0.45和0.50。
- 106周治疗期间未观察到任何不良事件发生率增加。
- 实验室变量评估显示预期变化,如中性粒细胞减少、肝酶升高和血脂升高。
- 开放标签扩展期间临床应答率保持稳定,疗效维持至第106周。
关键数值与推荐
- 疗效评估包括ACR20/50/70应答、DAS28(C反应蛋白)<3.2、CDAI缓解和低疾病活动度、SDAI缓解和低疾病活动度、HAQ-DI下降0.22单位及布尔2.0缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report long-term safety and tolerability of olokizumab (OKZ) in combination with methotrexate (MTX) in subjects with active rheumatoid arthritis (RA), using pooled data from three randomised clinical trials (RCT) followed by open-label extension (OLE) study. METHODS: Cumulative data from three phase 3 core trials and their OLE were analysed. Safety variables assessed included treatment-emergent adverse events (AEs), serious AEs (SAEs), AEs of special interest and laboratory results. Efficacy assessments included ACR20/50/70 responses, Disease Activity Score 28 (C-reactive protein) <3.2, CDAI remission and low disease activity (LDA), SDAI remission and LDA, HAQ-DI decrease of 0.22 unit and Boolean 2.0 remission. RESULTS: A total of 2304 patients received OKZ in combination with MTX either once every 2 weeks or once every 4 weeks. Event rates per 100 patient-years in OKZ every 2 weeks and OKZ every 4 weeks, respectively, were 9.57 and 9.13 for SAEs; 2.95 and 2.34 for serious infections; 0.09 and 0.05 for gastrointestinal perforations; 0.58 and 0.83 for major adverse cardiovascular events; and 0.45 and 0.50 for malignancies. No increase in the rate of any AE was observed over 106 weeks of treatment. The evaluation of laboratory variables demonstrated the expected changes, like neutropenia, elevation of liver enzymes and blood lipids. Clinical response rates remained stable during the OLE. CONCLUSION: The long-term safety and tolerability of OKZ in combination with MTX remained stable. The efficacy of OKZ was maintained through week 106. These findings support OKZ as a treatment option for patients with active RA.
引用
- Feist E, Fleischmann RM, Fatenejad S, et al. Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. Ann Rheum Dis. 2024. PMID: 38955475. doi:10.1136/ard-2023-225473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。